Publicaties
Gekozen filters:
Gekozen filters:
CD70 and PD-L1 in anaplastic thyroid cancer : promising targets for immunotherapy Universiteit Gent Universiteit Antwerpen KU Leuven
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients Vrije Universiteit Brussel Universiteit Hasselt Universiteit Antwerpen
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia Vrije Universiteit Brussel
Background. Criteria for good candidate antigens for immunotherapy of acute myeloid leukemia are high expression on leukemic stem cells in the majority of acute myeloid leukemia patients and low or non-existing expression in vital tissues. It was shown in vaccination trials that Receptor for Hyaluronic Acid Mediated Motility (RHAMM/HMMR) generates cellular immune responses in patients with acute myeloid leukemia, which correlate with clinical ...
Penile cancer: potential target for immunotherapy? KU Leuven
PURPOSE: Penile cancer (PeCa) is a rare malignancy with a poor prognosis in advanced disease. There is still a limited understanding of the biological mediators that are important in the prognosis and therapy of the disease. This review aims to provide a summary of the immune micro-environment, molecular oncogenesis and the role of HPV in the disease applying to the potential of the use of immunotherapy. METHODS: Narrative, non-systematic review ...
Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia Universiteit Antwerpen
B-cell acute lymphoblastic leukemia (B-ALL) is a rare heterogeneous disease characterized by a block in lymphoid differentiation and a rapid clonal expansion of immature, non-functioning B cells. Adult B-ALL patients have a poor prognosis with less than 50% chance of survival after five years and a high relapse rate after allogeneic haematopoietic stem cell transplantation. Novel treatment approaches are required to improve the outcome for ...